These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23084458)

  • 1. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders.
    Spooren W; Lindemann L; Ghosh A; Santarelli L
    Trends Pharmacol Sci; 2012 Dec; 33(12):669-84. PubMed ID: 23084458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Abnormalities of synaptogenesis in autism. Pathogenic and therapeutic implications].
    García-Peñas JJ; Domínguez-Carral J; Pereira-Bezanilla E
    Rev Neurol; 2012 Feb; 54 Suppl 1():S41-50. PubMed ID: 22374772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathways to drug development for autism spectrum disorders.
    Hampson DR; Gholizadeh S; Pacey LK
    Clin Pharmacol Ther; 2012 Feb; 91(2):189-200. PubMed ID: 22205199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel treatments in autism spectrum disorders: from synaptic dysfunction to experimental therapeutics.
    Canitano R
    Behav Brain Res; 2013 Aug; 251():125-32. PubMed ID: 23202136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?
    Guest PC; Martins-de-Souza D
    Adv Exp Med Biol; 2017; 974():49-67. PubMed ID: 28353224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment options for autism spectrum disorders in children and adolescents.
    Leskovec TJ; Rowles BM; Findling RL
    Harv Rev Psychiatry; 2008; 16(2):97-112. PubMed ID: 18415882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
    Baghdadli A; Gonnier V; Aussilloux C
    Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of autism spectrum disorders--autism and developmental disabilities monitoring network, six sites, United States, 2000.
    ;
    MMWR Surveill Summ; 2007 Feb; 56(1):1-11. PubMed ID: 17287714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of autism spectrum disorders.
    Benvenuto A; Battan B; Porfirio MC; Curatolo P
    Brain Dev; 2013 Feb; 35(2):119-27. PubMed ID: 22541665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autism, genetics and synaptic function alterations].
    Perche O; Laumonnier F; Baala L; Ardourel MY; Menuet A; Robin V; Mortaud S; Montécot-Dubourg C; Richard O; Pichon J; Briault S
    Pathol Biol (Paris); 2010 Oct; 58(5):381-6. PubMed ID: 20181440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapeutics of Tourette syndrome and stereotypies in autism.
    Rajapakse T; Pringsheim T
    Semin Pediatr Neurol; 2010 Dec; 17(4):254-60. PubMed ID: 21183132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and therapeutic challenges in autism spectrum disorders: insights from Rett syndrome.
    Castro J; Mellios N; Sur M
    Curr Opin Neurol; 2013 Apr; 26(2):154-9. PubMed ID: 23449173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate mediated signaling in the pathophysiology of autism spectrum disorders.
    Choudhury PR; Lahiri S; Rajamma U
    Pharmacol Biochem Behav; 2012 Feb; 100(4):841-9. PubMed ID: 21756930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of irritability in pervasive developmental disorders.
    Stigler KA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Autism spectrum disorders: updates and new definitions].
    Amitai M; Peskin M; Gothelf D; Zalsman G
    Harefuah; 2012 Mar; 151(3):167-70, 188. PubMed ID: 22519267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autism spectrum disorders in early childhood: an overview for practicing physicians.
    Carr JE; LeBlanc LA
    Prim Care; 2007 Jun; 34(2):343-59; abstract viii. PubMed ID: 17666231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sixty years of autism].
    van Berckelaer-Onnes IA
    Ned Tijdschr Geneeskd; 2004 May; 148(21):1024-30. PubMed ID: 15185436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.
    Hampson DR; Adusei DC; Pacey LK
    Biochem Pharmacol; 2011 May; 81(9):1078-86. PubMed ID: 21333634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pervasive developmental disorders not otherwise specified. A developmental-psychopathological approach for the development of made-to-measure treatment planning.
    Verheij F; van Loon H
    Acta Paedopsychiatr; 1992; 55(4):235-42. PubMed ID: 1492555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zinc deficiency dysregulates the synaptic ProSAP/Shank scaffold and might contribute to autism spectrum disorders.
    Grabrucker S; Jannetti L; Eckert M; Gaub S; Chhabra R; Pfaender S; Mangus K; Reddy PP; Rankovic V; Schmeisser MJ; Kreutz MR; Ehret G; Boeckers TM; Grabrucker AM
    Brain; 2014 Jan; 137(Pt 1):137-52. PubMed ID: 24277719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.